clinical trial · NCT07076199
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Novo Nordisk A/S·phase3·recruiting·n = 877
Diabetes Mellitus, Type 1Insulin icodecInsulin glargineInsulin aspart
brief summary
This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.
started
Aug 11, 2025
primary completion
Jan 25, 2027
completion
Mar 1, 2027
last updated
Jun 5, 2026
official title
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol